CCP
NBIX icon

Cardan Capital Partners’s Neurocrine Biosciences NBIX Stock Holding History

Cardan Capital Partners’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-29,289
Closed -$2.85M – 278
2021
Q1 		$2.85M Buy
+29,289
New +$3.07M 0.34% 88

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
DCP
DSM Capital Partners Palm Beach Gardens, Florida $5.84B AUM 22.63% 1-Year Est. Return

Cardan Capital Partners's NBIX Position: Q2 2021 in Review

Cardan Capital Partners sold out of Neurocrine Biosciences (NBIX) in Q2 2021, closing a stake of 29,289 shares — an estimated $2.85M sold.

Cardan Capital Partners first reported a position in NBIX in Q1 2021 and held it in 1 quarter. The position peaked at $2.85M in Q1 2021. 409 funds tracked by Wall St. Rank hold NBIX as of Q2 2021.

  • Cardan Capital Partners reported no remaining Neurocrine Biosciences position as of Q2 2021 after selling out during the quarter.
  • Cardan Capital Partners sold 29,289 Neurocrine Biosciences shares in Q2 2021, an estimated $2.85M.
  • Cardan Capital Partners first reported a position in Neurocrine Biosciences in Q1 2021 and held it in 1 quarter.
  • Cardan Capital Partners's Neurocrine Biosciences position peaked at $2.85M in Q1 2021.
  • 409 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2021.

Based on Cardan Capital Partners's 13F filing for Q2 2021, filed 20 Jul 2021.